Results 61 to 70 of about 1,602,420 (310)

The European Green Deal and the limits of ecological modernisation

open access: yesCulture, Practice & Europeanization, 2022
With the European Green Deal (EGD), the European Commission presented an ambitious roadmap for accelerated “ecological modernisation” in December 2019. Semantically, the EGD is linked to the New Deal and the debates surrounding the Green New Deal.
Tobias Haas   +2 more
doaj   +1 more source

Extraction of the index of refraction by embedding multiple and close small inclusions

open access: yes, 2016
We deal with the problem of reconstructing material coefficients from the farfields they generate. By embedding small (single) inclusions to these media, located at points $z$ in the support of these materials, and measuring the farfields generated by ...
Alsaedi, Ahmed   +4 more
core   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

open access: yesMolecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang   +8 more
wiley   +1 more source

Valuing Our National Parks: An Ecological Economics Perspective

open access: yesLand, 2019
The annual budget for the United States National Park Service was roughly $3 billion in 2016. This is distributed amongst 405 National Parks, 23 national scenic and historic trails, and 60 wild and scenic rivers.
Paul C. Sutton   +2 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Warren County, Kentucky - New Deal Programs, 1934-1935 (MSS 253) [PDF]

open access: yes, 2009
Finding aid only for Manuscripts Collection 253. Documents related to New Deal relief programs in Warren County, Kentucky and surrounding counties; correspondence of Ida Leighton Hodges, Bowling Green, Area Administrator of the Kentucky Emergency Relief ...
Folklife Archives, Manuscripts &
core   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

open access: yesMolecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed   +10 more
wiley   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

open access: yesMolecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj   +4 more
wiley   +1 more source

Green Governance - One Solution for two problems? Climate change and economic shocks: risk perceptions and coping strategies in China, India and Bangladesh [PDF]

open access: yes, 2010
This collection of papers is based on an international workshop held in the summer of 2009 at the University of Duisburg-Essen. It brings together different perceptions regarding China, India and Bangladesh as they face the risks and crises of climate ...
Reinhardt, Dieter, Senz, Anja
core  

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Home - About - Disclaimer - Privacy